Article Text

Download PDFPDF
A population based dynamic approach for estimating the cost effectiveness of screening for Chlamydia trachomatis
  1. R Welte1,
  2. M Kretzschmar2,
  3. J A R van den Hoek3,
  4. M J Postma4
  1. 1Department of Health Economics, University of Ulm, Ulm, Germany
  2. 2Department of Infectious Diseases Epidemiology, National Institute of Public Health and the Environment, Bilthoven, The Netherlands
  3. 3Municipal Health Service Amsterdam, Amsterdam, The Netherlands
  4. 4Groningen University Institute for Drug Exploration/University of Groningen Research Institute of Pharmacy, Groningen, The Netherlands
  1. Correspondence to:
 Dr Postma, Groningen University, Institute for Drug Exploration/University of Groningen, Research Institute of Pharmacy, Groningen, The Netherlands; 

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

With great interest, we have read the recent paper in STI on cost effectiveness for Chlamydia trachomatis screening by Honey et al.1 We concur with their conclusion that more data derived from clinical trials are needed for policy making, particularly when considering the evidence on the subsequent risk of pelvic inflammatory disease (PID) in women who test positive for Chlamydia trachomatis.

Our paper2 was included and discussed in this review. As our approach was rather complex, we note that some parts of our design and results may have been misinterpreted. Honey et al note that our study was focused on screening both men and women in general practice with an age range for …

View Full Text